Alexander_Gutmans

Engimmune Therapeutics raises CHF 15.5m in seed financing round 

Swiss biotech company, Engimmune Therapeutics completes its seed financing round raising CHF 15.5 million, co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch. 

Engimmune Therapeutics is a platform company using cutting-edge technologies to engineer highly potent and specific TCR-based therapies for cancer treatment. 

Proceeds from the financing will be used to develop novel T-cell receptor therapeutics and  further build Engimmune Therapeutics’ pipeline, expand the research team in Switzerland and build a foothold in Denmark, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs. 

Walder Wyss advises Engimmune Therapeutics in connection with the financing round. The team includes Alexander Gutmans (partner, corporate/m&a and venture capital, pictured), Karina Tschon (associate, corporate/m&a and venture capital), Lena Götzinger (associate IP/licensing), Lucas Maurer (associate, corporate/m&a and venture capital) and Michelle Bruni (senior associate, corporate/m&a and tax). 

Suzan Abdien Hago Taha

SHARE